Company: Lucid Reality Labs, Miami, FL
Company Description: Lucid Reality Labs, the World's leading Immersive Technology consulting, design and development company, creates immersive XR training and simulations for Healthcare, MedTech and Pharma. The team delivered 250+ XR projects and dedicated over 1,000,000 hours to honing technological expertise in the XR domain to help businesses and institutions innovate and digitalize.
Nomination Category: New Product & Service Categories - Business Technology
Nomination Sub Category: Emerging Technology
 Nomination Title: Lucid Reality Labs “Seeing the Problem"
- Which will you submit for your nomination in this category, a video of up to five (5) minutes in length about the nominated new or new-version product or service, OR written answers to the questions for this category? (Choose one):
Written answers to the questions
- If you are submitting a video of up to five (5) minutes in length, provide the URL of the nominated video here, OR attach it to your entry via the "Add Attachments, Videos, or Links to This Entry" link above, through which you may also upload a copy of your video.
- If you are providing written answers for your submission, you must provide an answer to this first question: If this is a brand-new product, state the date on which it was released. If this is a new version of an existing product, state the date on which the update was released:
"Seeing the Problem" The Extended Reality (XR) Ophthalmology Macular Disease Simulation is a brand-new product that was developed by Lucid Reality Labs in collaboration with pharmaceutical company Roche [REDACTED FOR PUBLICATION].
- If you are providing written answers for your submission, you must provide an answer to this second question: Describe the features, functions, and benefits of the nominated product or service (up to 350 words):
Total 350 words used.
"Seeing the Problem" The Extended Reality (XR) Ophthalmology Macular Disease Simulation developed by Lucid Reality Labs in collaboration with the pharmaceutical company Roche. A unique immersive tool was built to demonstrate Macular Disease (AMD) conditions in real time. It helps users to experience and learn what it is like to live these symptoms and faces everyday life challenges. The product aims to raise awareness and recognition of macular disease conditions among healthcare practitioners, patient associations, and the general public to facilitate understanding, bring attention and help prevent macular disease in its early stages.
The product was built using visual materials and medical specialists' insights and patient feedback to ensure accurate condition representation. The XR experience was developed using one of the most advanced mixed reality headsets on the market – Varjo XR-3, with the highest visual fidelity. Experience utilized the device's eye-tracking, making it impossible to avert from the symptoms and see-through capabilities that overlayed the real-life objects and surroundings with the condition symptoms in real-time (visual distortions, increased blurriness of printed words, and well-defined blind spot in their field of vision).
The main benefit of this product is that for the first time in the history of ophthalmology, healthcare practitioners, medical students, and patient associations obtained an opportunity to experience the macular disease condition first-hand. It allows helping identify an early diagnosis and prevent the condition deterioration. Although no cure currently exists for AMD, timely treatment may slow down the disease and diminish the severity of vision loss. This illness impacts nearly 11 million people in the US alone and remains one of the most common conditions causing sight loss. The number of people living with the illness worldwide is estimated to reach 288 million by 2040.
The Extended Reality (XR) Ophthalmology Simulation" was highly praised during presentations, as participants could experience the macular disease conditions, feel and engage in the daily routine of a person suffering from this condition and empower further steps to improve care for such patients."
- If you are providing written answers for your submission, you must provide an answer to this third question: Outline the market performance, critical reception, and customer satisfaction with the product or service to date. State monetary or unit sales figures to date, if possible, and how they compare to expectations or past performance. Provide links to laudatory product or service reviews. Include some customer testimonials, if applicable (up to 350 words):
Total 136 words used.
“Seeing the Problem" The Extended Reality (XR) Ophthalmology Macular Disease Simulation was presented to drove active communication around the eye care topic. The presentation involved governors, professional associations and practitioners, and journalists. [REDACTED FOR PUBLICATION]
This XR solution paves the way for technology into some currently neglected or underfunded social problems, which can be addressed by using immersive technology and changing the quality of lives of millions worldwide. Please find the links to the testimonials/posts via the following links:
[REDACTED FOR PUBLICATION]
- You have the option to answer this final question: Reference any attachments of supporting materials throughout this nomination and how they provide evidence of the claims you have made in this nomination (up to 250 words):
Total 115 words used.
1. “Seeing the Problem" The Extended Reality (XR) Ophthalmology Macular Disease Simulation ~ V2 https://www.youtube.com/watch?v=5xSBCLOTHX8
This video demonstrates the immersive experience created by Lucid Reality Labs to present its users with a visual impairment called macular disease and provides an overview of the problem in the UK. It helps understand how virtual reality can help spread awareness and find solutions for this illness.
2. Simulation recording shows the macular disease's condition through the eyes of a person suffering from it. It helps understand how challenging the simple daily routine can be and emphasizes the urgency of addressing this issue. [REDACTED FOR PUBLICATION]
| Attachments/Videos/Links: |
|---|
|
